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Abstract
Background: Neurotrophins elicit both acute and long-term modulation of synaptic transmission and plasticity.
Previously, we demonstrated that the long-term synaptic modulation requires the endocytosis of neurotrophin-
receptor complex, the activation of PI3K and Akt, and mTOR mediated protein synthesis. However, it is unclear
whether the long-term synaptic modulation by neurotrophins depends on protein synthesis in pre- or post-
synaptic cells.
Results: Here we have developed an inducible protein translation blocker, in which the kinase domain of protein
kinase R (PKR) is fused with bacterial gyrase B domain (GyrB-PKR), which could be dimerized upon treatment with
a cell permeable drug, coumermycin. By genetically targeting GyrB-PKR to specific cell types, we show that NT-3
induced long-term synaptic modulation requires presynaptic, but not postsynaptic protein synthesis.
Conclusions: Our results provide mechanistic insights into the cell-specific requirement for protein synthesis in the
long-term synaptic modulation by neurotrophins. The GyrB-PKR system may be useful tool to study protein
synthesis in a cell-specific manner.
Background
Synaptic plasticity, or activity-dependent morphological
and functional modification of synaptic connections, is
the dominant underlying mechanism for brain function
[1]. Recently, neurotrophins, a family of structurally and
functionally related proteins, that include nerve growth
factor (NGF), brain derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), and neurotrophin-4/5(NT-4/5),
have emerged as major modulators involved in synaptic
plasticity [2-4]. Similar to synaptic plasticity, synaptic
effects of neurotrophins can be divided into two tempo-
rally distinct modes: the acute effect occurring within
seconds or minutes upon a neurotrophin exposure, and
the long-term effect taking hours and days to accom-
plish [5-7]. Previously, we identified that the acute and
long-term effects of NT-3 are operated by distinct mole-
cular and cellular mechanisms by using Xenopus cul-
tured neuromuscular synapse [6,8]. Compared to acute
effects, NT-3 mediated long-term synapse modulation
requires endocytosis of NT-3-TrkC (a cognate receptor
for NT-3) complex, activation of Akt, a major down-
stream kinase of PI3K pathway, and mTOR dependent
protein synthesis [6].
The requirement for protein synthesis assumes that
NT-3 can trigger protein synthesis which can occur in
presynaptic neurons or postsynaptic muscle cells [9].
Because conventional pharmacology cannot inhibit pro-
tein synthesis in a cell-type specific manner, we devel-
oped and utilized an inducible protein translation blocker
that can be genetically targeted to specific cells to further
investigate whether NT-3 induced long-term synaptic
modulation requires either presynaptic or postsynaptic
protein synthesis [10]. Our protein synthesis inhibitor
system utilizes the double-stranded (ds) RNA-dependent
protein kinase (PKR), which reversibly phosphorylates
the a subunit of eukaryotic initiation factor-2 (eIF2a)t o
control protein synthesis in eukaryotic cells [11]. The
kinase activity of PKR is very low at rest, but is signifi-
cantly induced upon binding of its dsRNA-binding
domains to dsRNAs during viral infection, leading to
dimerization, autophosphorylation, activation of the
kinase, and eventual blockade of general mRNA transla-
t i o n[ 1 2 ] .T oe s t a b l i s ha ni n d ucible system, we utilized
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upon treatment with a cell permeable drug, coumermy-
cin [13]. By using this unique system that allows specific
inhibition of general mRNA translation only on expres-
sing cells, we show that NT-3 induced long-term synaptic
modulation requires presynaptic, but not postsynaptic
protein synthesis. Taken together, these results suggest
general principles that govern long-term regulation of
synapses by neurotrophins.
Results
GyrB-PKR, an inducible molecular system to block protein
synthesis
Previously, we found that the rapamycin (200 nM), a spe-
cific inhibitor for mTOR, blocked NT-3 induced long-
term synapse modulation [6]. Pharmacological inhibitors
may elicit side effects in addition to its inhibition of pro-
tein synthesis [14,15]. It is also unclear whether rapamy-
cin acts pre- or postsynaptically. Here we attempted to
develop a genetic approach to examine the importance of
protein synthesis in NT-3-induced synaptic modulation.
The dimerization of PKR kinase domain has been shown
to be both necessary and sufficient to activate its kinase
function [13], which could suppress protein synthesis by
phosphorylating eIF2a, leading to the dissociation of
eIF2-tRNA-40 S complex [11]. We replaced dsRNA-
binding domain of PKR with E. coli protein gyrase B,
which could be dimerized upon exposure to the cell-
permeable ligand coumermycin [16]. This fusion protein
GyrB-PKR should therefore in theory confer inducible
and reversible inhibition of protein synthesis upon treat-
ment with coumermycin (Figure 1A).
To determine whether coumermycin truly induced
dimerization and activation of GyrB-PKR, we expressed
GyrB-PKR in developing Xenopus embryos by blasto-
mere injection techniques [17]. Western blot analysis
was used to monitor the expression of GyrB-PKR and
phosphorylation of eIF2a, a direct downstream target of
PKR, upon treatment with coumermycin at various con-
centrations and durations. Addition of 0.1 μMc o u m e r -
mycin caused eIF2a phosphorylation (Figure 1B). The
half-maximum response (EC50) value for coumermycin-
induced eIF2a phosphorylation was 1 μM, which was
measured 8 hours after drug treatment (Figure 1C).
Coumermycin treatment led to a robust eIF2a phos-
phorylation as early as 5 min, which lasted more than
10 hours (Figure 1D and 1F). Moreover, when coumer-
mycin was removed 2 hours after its application, the
eIF2a phosphorylation began to decline at 4-hour and
reached baseline levels at 10-hour (Figure 1E and 1F).
Taken together, these experiments indicate that the
expression of GyrB-PKR results in inducible and reversi-
ble phosphorylation of eIF2a upon coumermycin
treatment.
Next, we investigated whether the dimerization and
subsequent activation of PKR inhibits new protein
synthesis. Due to limited number of cells available in
these nerve-muscle co-cultures, it was not feasible to
directly measure protein synthesis using conventional
approaches, such as
3H-leucine incorporation. Thus, we
utilized a destabilized green fluorescence protein (pd1-
EGFP, half live = 1 hour) whose fluorescence fades if
protein synthesis is blocked. In pd1-EGFP, the residues
422-461 of mouse ornithine decarboxylase (MODC)
were fused to the C terminus of EGFP to enable a rapid
protein degradation and turnover [18]. Therefore, by
measuring GFP fluorescence change, we could monitor
steady-state levels of GFP proteins, which should corre-
late with the degree of general protein synthesis. When
pd1-EGFP was expressed in spinal neurons by embryo
injection (Figure 2A), treatment of the cultures with the
general protein synthesis inhibitor rapamycin (200 nM)
or cyclohexamide (60 μM) for 1 hour greatly reduced
fluorescence intensity as a consequence of the inhibition
of new EGFP synthesis, which indicated the feasibility of
monitoring protein synthesis using this assay (data not
shown) [19].
To determine whether coumermycin treatment inhi-
bits protein synthesis in cultured spinal neurons, we
expressed pd1-EGFP with or without Gyr-PKR in Xeno-
pus spinal neurons and monitored the changes in fluor-
escent intensity upon coumermycin treatment. Indeed,
coumermycin treatment reduced the GFP fluorescent
intensity by 45% in spinal neurons only when pd1-EGFP
co-expressed with GyrB-PKR (Figure 2B). Taken
together, these results demonstrate that coumermycin
induced dimerization of PKR effectively phosphorylates
eIF2a and subsequently blocks new protein synthesis.
Presynaptic protein synthesis in NT-3-induced synaptic
modulation
At the Xenopus neuromuscular synapses, application of
exogenous NT-3 at a high concentration (50 ng/ml)
induces a rapid potentiation of synaptic transmission
within 5 min [20,21], whereas long-term treatment with
a lower concentration of NT-3 (5 ng/ml; 2 days) facili-
tates physiological and morphological maturation of the
synapses [6,8,17]. We recorded spontaneous synaptic
currents (SSCs) in 1-d old nerve-muscle co-culture
using whole-cell voltage clamp recording techniques. As
reported, acute application of NT-3 elicited a marked
increase in transmitter release in neurons (Figure 3A,
b o t t o m ) .T h es a m et r e a t m e n ti nt h ep r e s e n c eo fc o u -
mermycin didn’t affect NT-3 mediated acute effect, indi-
cating that coumermycin itself did not affect synaptic
transmission (Figure 3C, columns 3&4).
The embryo injection technique allows selective
expression of GyrB-PKR in either presynaptic motor
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expressed GFP fluorescence, at neuromuscular synapses
i nt h en e r v e - m u s c l ec o - c u l t u r e( F i g u r e3 B ) .U s i n gt h i s
system, we tested whether activation of GyrB-PKR either
presynaptically or postsynaptically alters the NT-3 effect.
When GyrB-PKR was expressed in the postsynaptic
muscle cells, application of NT-3 in the presence of
coumermycin had no effect on the acute synaptic poten-
tiation induced by NT-3 (Figure 3C, columns 5-8). Simi-
larly, the expression of GyrB-PKR in presynaptic motor
neurons also failed to alter the NT-3 effect in coumer-
mycin treated cultures (Figure 3C, columns 9-12). These
Figure 1 Phosphorylation of eIF2a upon coumermycin-induced GyrB-PKR dimerization. (A) Schematic diagrams showing the fusion of PKR
kinase domain with coumermycin-binding domain of GyrB. Application of coumermycin (C. mycin) induces the dimerization of the PKR fusion
proteins and activates PKR, triggering eIF2a phosphorylation and subsequent de novo protein synthesis inhibition. (B) Representative blots
showing C.mycin-induced phosphorylation of eIF2a on Ser51 in Xenopus embryos expressing GyrB-PKR. Embryos were treated with various
concentrations of coumermycin for 8 hours, harvested and lysed. Western blotting was performed using specific antibodies as indicated. The
blots were also probed with anti-eIF2a and anti-tubulin antibody for loading controls. (C) Quantification of eIF2a phosphorylation with different
C.mycin concentrations. (D) Time course of eIF2a phosphorylation induced by 1 μM Coumermycin. (E) Time course of eIF2a phosphorylation
upon 1 μM C.mycin treatment and withdrawal. Embryos were treated with Coumermycin for 2 hours and washed with culture medium without
C.mycin (F) Quantification of eIF2a phosphorylation with or without C.mycin at different time points. Arrow indicated the time point of
withdrawing C.mycin. Note the eIF2a phosphorylation level goes back to the baseline within 8 hours. Multiple blots were quantified (N = 6), and
eIF2a-P signals at various time points were normalized to that at “0” hour.
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tion by NT-3 does not require protein synthesis.
Next, to determine whether pre- or post-synaptic pro-
tein synthesis is necessary for NT-3 mediated long-term
synaptic modulation, we expressed GyrB-PKR in either
spinal neurons or myocytes using the same embryo
injection techniques described above. Cultures were
incubated with NT-3 (5 ng/ml) for 2 days with or
without coumermycin as indicated (Figure 4A). At naive
synapses, coumermycin treatment did not affect basal
synaptic transmission nor prevent the long-term poten-
tiating effect of NT-3 (Figure 4B, columns 3&4). Expres-
sion of GyrB-PKR in either presynaptic spinal neurons
(Figure 4B, columns 5&6) or postsynaptic muscle cells
(Figure 4B, columns 9&10) without coumermycin treat-
ment did not alter the long-term effect of NT-3. Intrigu-
ingly, coumermycin treatment completely blocked the
long-term effect of NT-3 in synapses made by spinal
neurons expressing GyrB-PKR (Figure 4B, columns
11&12). However, the same treatment was ineffective if
GyrB-PKR was expressed in postsynaptic myocytes
(Figure 4B, columns 7&8). Taken together, these results
suggest that protein synthesis in the presynaptic spinal
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Figure 2 Inhibition of protein translation in spinal neurons by
C.mycin -induced GyrB-PKR dimerization. (A) Expression of the
pd1-EGFP in Xenopus spinal neurons. Bright field, fluorescent, and
merged images (left, middle, right, respectively) show a spinal
neuron and muscle cells expressing pd1-EGFP. N: neuron; M: muscle
cell. Bar, 10 μm. (B) Quantification of fluorescence change on
neurons. Pd1-EGFP was expressed either alone or together with
GyrB-PKR in Xenopus spinal neurons, using embryo injection
techniques. C.mycin was applied to the culture dish at time “0”, and
pd1-EGFP fluorescence was monitored over time. The number of
experiments performed was indicated in the legend.
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Figure 3 Normal acute synaptic potentiation by NT-3 in GyrB-
PKR activated neuromuscular synapses. (A) Sample recordings
showing acute synaptic potentiation by NT-3. NT-3 (50 ng/ml) was
applied directly to 1-day-old nerve-muscle co-culture. The frequency
of spontaneous synaptic currents (SSCs) was used to monitor
changes in synaptic efficacy. (B) A sample image showing
neuromuscular synapses in which muscle cells are innervated by a
GFP expressing spinal neuron. N: neuron axon (neuron body is out
of this image); M: muscle cell. Bar, 10 μm. (C) Summary of acute
effect of NT-3 on synapses without GyrB-PKR expression, and
synapses with presynaptic or postsynaptic expression of GyrB-PKR.
Each data point represents SSCs frequency (averaged from 30 min
of recording) from a single synapse before C.mycin and after NT-3
application. Note that the application of coumermycin did not
affect the baseline of recording. The number associated with each
column represents the number of cells analyzed. Data are presented
as the mean ± the SEM.
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NT-3 mediated long-term synaptic modulation at neu-
romuscular synapses.
Discussion
Targeting protein synthesis inhibition to specific cells
We have previously described an inducible PKR system
that is based on dimerization of FKPB-PKR induced by
the synthetic ligand AP20187 [10,22]. Here we report a
similar system based on GyrB-PKR induced by coumer-
mycin. Both systems have a major advantage over the
conventional pharmacological inhibition of protein
synthesis: genetically targeting to a specific cell popula-
tion. This is particularly valuable in heterogeneous sys-
tem in which cell-cell interaction is prominent, such as
pre- and postsynaptic interactions in the nervous sys-
tem. The GyrB-PKR system is attractive in several ways.
First, coumermycin is an antibiotic that is not toxic to
vertebrate cells. In our hands, incubation with coumer-
mycin at 1 μM for two days showed no obvious adver-
sary effect to the nerve-muscle cultures (unpublished
observations). Second, in the GyrB-PKR fusion con-
struct, the dsRBD is removed and replaced it with GyrB,
a bacterial protein that dimerizes upon binding to cou-
mermycin. This modification prevents non-specific acti-
vation of PKR by other agents. Third, the only clearly
verified substrate of PKR is the eukaryotic translation
initiation factor eIF2a [13]. Phosphorylation of Ser51 on
eIF2a converts it from a substrate to a competitive inhi-
bitor of the guanine-nucleotide exchange factor eIF2B,
blocking general mRNA translation. Activation of PKR
therefore represents a specific inhibition of protein
synthesis with relatively few side effects. Finally, using
embryo injection techniques, we show that the GyrB-
PKR system is very useful in selective inhibition of pro-
tein synthesis in pre- or postsynaptic cells. Taken
together, the GyrB-PKR system offers an alternative way
to inducibly and reversibly block protein synthesis in
the targeted cells, allowing applications in situations
when AP20187 could not be used.
Pre- and postsynaptic protein synthesis in synaptic
modulation
Compelling evidence suggests that one of the fundamen-
tal differences between acute and long-term synaptic
modulation by neurotrophins is the requirement for pro-
tein synthesis. Acute potentiation of synaptic transmis-
sion by NT-3 is completely insensitive to translation
inhibitors such as anisomycin and cycloheximide [23]. In
contrast, the long-term form of NT-3 mediated synaptic
modulation, including both structural (synaptic varicos-
ity) and functional (synaptic currents) changes, requires
protein synthesis. Bath application of rapamycin, a
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Figure 4 Blockade of the long-term synaptic effect of NT-3 by
C.mycin -induced PKR activation. (A) Sample recordings showing
long-term synaptic potentiation by NT-3. The Xenopus nerve-muscle
co-cultures were grown in the presence or absence of NT-3 (5 ng/
ml) for 2 days. Expression of GyrB-PKR alone did not prevent NT-3-
mediated long-term synaptic potentiation. However, application of
C.mycin to synapses expressing GyrB-PKR presynaptically completely
prevented long-term synaptic potentiation by NT-3. (B) Summary of
long-term effect on NT-3 on synapses without GyrB-PKR expression,
and synapses with pre- or post-syanptic expression of GyrB-PKR.
Each data point represents SSCs frequency (averaged from 30 min
of recording) form a single synapse with or without coumermycin
treatment. Note that application of C.mycin alone could not
attenuate the increase in SSC frequency by NT-3 chronic treatment.
Application of C.mycin to synapses expression GyrB-PKR
presynaptically, but not postsynaptically, completely prevented long-
term synaptic effect of NT-3. The number associated with each
column represents the number of cells analyzed. Data are presented
as the mean ± the SEM.
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reversed the morphological and physiological changes
induced by long-term exposure to NT-3 [6]. The major
contribution of the present study is to demonstrate that
at the developing neuromuscular synapses, it is the pro-
tein synthesis in the presynaptic motor neurons, but not
in postsynaptic muscle cells, that mediates NT-3 induced
long-term synaptic modulation. We show that coumer-
mycin can effectively block the NT-3 effects only when
the GyrB-PKR is selectively expressed in the pre- but not
in postsynaptic cells. This finding indicates that NT-3 sti-
mulates protein synthesis in presynaptic neurons, supply-
ing the necessary proteins to enhance synaptic functions.
It remains to be investigated whether the increase in pro-
tein synthesis occurs at the motor neuron soma, or in the
motor axons or terminals. It should be note that protein
synthesis in the presynaptic axon was reported to be
involved in activity-dependent synaptic plasticity in sen-
sory motor synapse in Aplysia and mature crayfish neu-
romuscular junctions [24,25].
Similar to neurotrophin-induced synaptic potentiation
at the neuromuscular synapses, late-phase long-term
potentiation (L-LTP) at the hippocampal CA1 synapses
also depends on protein synthesis [5,26]. By injecting
FKBP-PKR-expressing virus into CA1, but not CA3, of
hippocampus in vivo, our previous study demonstrated
that postsynaptic, but not presynaptic, inhibition of pro-
tein synthesis blocks L-LTP [10]. These results suggest
that at the CA1 synapses in the hippocampus, protein
synthesis in the postsynaptic CA1 neurons, rather than
presynaptic CA3 neurons, is critical in maintaining
L-LTP [10]. Thus, for long-term synaptic modulation,
there is no set rule for the requirement of protein synth-
esis in pre- or postsynaptic site.
Conclusion
We developed an inducible protein synthesis blocker
that can be genetically targeted to specific types of cells.
By using this novel molecular tool, we have identified
that presynaptic protein syn t h e s i si sc r u c i a lf o rN T - 3 -
mediated long-term synaptic modulation in Xenopus
neuromuscular synapses. Our findings elucidate
mechanistic insights into the cell-specific requirement
for protein synthesis in the long-term synaptic modula-
tion by neurotrophins.
Methods
DNA constructs, Xenopus embryo injection, nerve-muscle
co-culture and whole-cell patch clamp recording
GyrB-PKR construct, which contains a bacterial gene
GyrB fused with the kinase domain of PKR (GyrB-PKR,
Figure 1A), was described previously [13]. Capped
GyrB-PKR mRNAs were synthesized using mMessage
machine (Ambion), mixed with GFP mRNA (1 mg/ml)
in a 1:1 ratio, and injected into one blastomere at the
2- or 4-cell stage embryos using the Picospitzer pressure
ejector as described [6].
Nerve-muscle cultures were prepared one day after
injection [6]. Briefly, neural tubes and associated myoto-
mal tissues of Xenopus embryos at stage 20 were disso-
ciated in Ca
2+-Mg
2+-free medium (58.2 mM NaCl,
0.7 mM KCl, and 0.3 mM EDTA, pH 7.4) for 15-20
min. Cells were plated on clean glass coverslips, and
grown in the presence or absence of NT-3 (5 ng/ml, gift
from Regeneron Phamaceuticals) for 2 days at room
temperature. Coumermycin, which induces GyrB-PKR
dimerization, was added 1 hour before NT-3 treatment.
The culture medium consisted (vol/vol) of 50% L-15
medium, 1% fetal calf serum and 49% Ringer’ss o l u t i o n
(117.6 mM NaCl, 2 mM CaCl2, 2.5 mM KCl, 10 mM
HEPES, pH 7.6).
Synaptic currents were recorded from innervated mus-
cle cells in 1 or 2-day old cultures by the whole-cell
patch clamp recording in culture medium at room tem-
perature [8]. The internal pipette solution contained
150 mM KCl, 1 mM NaCl, 1 mM MgCl2 and 10 mM
HEPES buffer (pH 7.2). The membrane potentials of the
muscle cells recorded were generally in the range of -55
to -75 mV and were voltage clamped at -70 mV. All
data were collected by an Axonpatch 200B patch clamp
amplifier (Molecular Devices), with a current signal filter
set at 3 kHz. The frequency of spontaneous synaptic
currents (SSCs) was defined as the number of SSC
events per minutes. The frequency and amplitude of
SSCs were analyzed using Clampfit software (Molecular
Devices). Pipette and membrane capacitance and serial
resistance were compensated.
Western blot analysis
Western blotting was performed as described [8]. Xeno-
pus embryos at stage 20-22 were quickly homogenized
in the extraction buffer (100 mM NaCl, 50 mM Tris-
HCl, pH7.5, 1% NP-40, 2 mM PMSF, 1 mg/ml aproti-
nin, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 2 M
Na3VO4) and subsequently sonicated. The insoluble pel-
let after high-speed centrifugation was discarded and the
resulting supernatants were transferred to fresh tubes
containing 300 ml freon (1,1,2-trichlorotrifluoroethane)
(Sigma), vortexed for 1 min, incubated on ice for 5 min-
utes, and subsequently centrifuged to remove yolk pro-
tein. Next, protein concentrations were determined
using the Bradford protein assay kit (BioRad). Proteins
were separated by SDS-polyacrylamide electrophoresis,
and blotted onto Immobilon-P membrane (Millipore)
with Semi-dry gel transfer apparatus (BioRad). The blots
were incubated overnight at 4°C with primary antibodies
including anti-PKR (1:1000) (Cell Signaling Technology),
anti-phosphorylated form of eIF2a (1:1000) (Assay
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Signaling). Next, blots were incubated with secondary
antibodies conjugated with HRP (Jackson Immunore-
search) and signals were detected by chemiluminescence
kit (GE healthcare).
Protein synthesis inhibition assay
Destabilized EGFP vector (pd1EGFP-N1 from clontech)
was used to monitor new protein synthesis in Xenopus
spinal neurons. In the pd1EGFP, residues 422-461 of
mouse ornithine decarboxylase (MODC) were fused to
the C terminus of EGFP and this region of MODC con-
tains a PEST amino acid sequence that targets the pro-
tein for degradation, resulting in rapid protein turnover.
This PEST amino acid sequence of MODC is highly
conserved in Xenopus, mice and human. It is correlated
with most short-lived proteins [27]. pd1EGFP has a
half-life of approximately one hour, as measured by
fluorescence intensity of cells treated with the protein
synthesis inhibitor cycloheximide [18]. pd1EGFP and/or
GyrB-PKR were expressed in Xenopus spinal neurons by
embryo injection. Images were collected with 40× objec-
tive lens (NA 1.0) on a fluorescence microscopy. Fluor-
escence intensity from a small region of interest (ROI, 6
pixels by 6 pixels, or 1.0 × 1.0 μm) on a single neuronal
soma was measured and analyzed. The pd1EGFP asso-
ciated fluorescence was calculated by subtracting the
fluorescence intensity in background (cell-free) area
from the averaged intensity of three different ROIs on
neuronal soma. ROIs were initially positioned by eye
and corrected for the center of mass of each soma by an
automated script in IPLab (Scanalytics). Before drug
treatment, average intensities from 3 time frames were
considered as an initial fluorescence level. Next, using
time-lapse microscopy, images are collected and the
fluorescence intensity of each frame was recorded.
Fluorescence puncta in one neuron were pooled and
averaged. Student t-test was used to analyze average
intensity between groups.
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